Yoshiro Saito

National Institute of Infectious Diseases

Papers

1

Total Citations

35

H-Index

1

About

Yoshiro Saito is a leading figure in cancer biomarker research, with a primary focus on improving treatment outcomes for pancreatic cancer through personalized medicine. His work centers on identifying predictive biomarkers that can guide therapeutic decisions, particularly for patients receiving gemcitabine-based chemotherapy. In his highly cited 2010 study, Saito employed liquid chromatography-mass spectrometry (LC-MS) to analyze baseline patient profiles, successfully uncovering novel biomarkers capable of predicting overall survival in advanced pancreatic cancer patients. This contribution addresses a critical clinical challenge: while gemcitabine remains a standard treatment, patient responses vary dramatically, and many derive little benefit. By enabling earlier identification of non-responders, Saito’s research helps spare patients from ineffective therapies and associated toxicities. His work has garnered significant attention, with his most influential paper accumulating 35 citations, reflecting its impact on the field. Through these efforts, Saito continues to advance the promise of precision oncology, striving to transform pancreatic cancer care from a one-size-fits-all approach to a more targeted, patient-specific strategy.

Research Focus

Key Achievements

1
H-Index
1
Papers
35
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment
35 citations · 2010
📈 Most Prolific Year: 2010 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: National Institute of Infectious Diseases

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago